The early diagnosis of Alzheimer’s disease: a patient-centred conversation with the care team
Raising the bar in Drug-resistant Focal Onset Seizures: any improvements in sight?
Have we realised the full potential of S1P receptor modulation in MS?
Clinical conversations in migraine - we can help!
Adults with SMA: the beginning of a new chapter
Advancing MS Care: Addressing the Patient Experience
New perspectives in the management of rare early-onset epilepsies: beyond seizures
Removing the barriers to optimal migraine care: Are we listening to the evidence?
We need to talk about Brain Health and Alzheimer’s
Motor fluctuation management: now and what next?
Complement inhibition in neuromyelitis optica spectrum disorder and refractory generalized myasthenia gravis; From trials to real-world clinical practice
Partnering with patients from the start of the MS journey: Priorities, practicalities and progress
Overcoming barriers in MS care: optimising treatment for patients
AbbVie: Personalizing Care for Patients With Parkinson’s Disease and Uncontrolled Symptoms: Optimizing Identification and Joint Treatment Decisions
Current and future approaches to migraine prevention
Gene, Patient, Clinician: Principles of Targeted Therapies in Spinal Muscular Atrophy (SMA)
ATTR amyloidosis – navigating this multifaceted disease
Managing Epilepsy in a COVID world
AMBER: Plasma Exchange plus albumin replacement as an innovative treatment for Alzheimer’s disease
Implications of the first Ex-vivo Gene therapy approved for treating early onset MLD’
Continuing tales of the unexpected; unravelling the mystery of an earlier diagnosis in muscle disease
Transforming outcomes and the goals for care in the 21st century
The evolution of infusion therapy for PD – translating clinical progress into personalised solutions
Balancing COVID-19 challenges and long-term treatment of MS
Management of Relapsing-Remitting Multiple Sclerosis with an S1P Receptor Modulator
The Effect of an S1P Receptor Modulator on Cognitive Processing in Patients with Relapsing-Remitting Multiple Sclerosis
Quantitative Brain Volume Assessment: Past, Present, and Future
Clarity on cannabinoids: test your knowledge
How important is an evidence-based approach for cannabis-based products and medicines?
Conversations on cannabinoids: tackling the big questions
The hidden drivers of disease progression: peering behind the blood brain barrier
Unmasking spms: challenging the dogma
Facing the challenge: managing disease progression
Starting the AD journey: identifying a potential patient
Continuing the AD journey: providing a diagnosis
Overseeing the AD journey: treating and monitoring care
Adults with SMA: To treat or not to treat?
Genetic ALS − Epidemiology and testing
Adults with SMA: How to define treatment response?
One to 14: the heterogeneity and consequences of episodic migraine
Chronic migraine: more than a headache
Medication-overuse headache (MOH): when the treatment becomes the problem
The future of migraine treatment paradigm
TIME-LAPSE. Living with the impact of generalised myasthenia gravis
Gene Therapy: Neurology to Lead or Follow?
Best practice in management of patients with Lennox-Gastaut syndrome on cannabidiol: experts’ clinical cases
GENE THERAPY: addressing the unmet needs of neuromuscular disorders
Resolution, reproducibility, noise and quality of electrodiagnostic recordings
